Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at...
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire VICTORIA, BC, May 8, 2024...
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board Canada NewsWire VICTORIA, BC, May 2, 2024 --Advisory Board to Provide...
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 PR...
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire VICTORIA, BC, April 8, 2024...
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today Canada NewsWire VICTORIA, BC, April 5, 2024 VICTORIA, BC, April 5, 2024 /CNW/ - Eupraxia...
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024 Canada NewsWire VICTORIA, BC, April 3, 2024 Company's Listing...
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results PR Newswire VICTORIA, BC, April 1, 2024 VICTORIA, BC, April 1, 2024...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.